CNSX:STIL

Stock Analysis Report

Executive Summary

StillCanna Inc., a life sciences company, focuses on cannabidiol extraction in Europe.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has StillCanna's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-9.2%

STIL

-2.1%

CA Pharmaceuticals

-0.3%

CA Market


1 Year Return

-29.4%

STIL

-46.2%

CA Pharmaceuticals

4.8%

CA Market

Return vs Industry: STIL exceeded the Canadian Pharmaceuticals industry which returned -46.2% over the past year.

Return vs Market: STIL underperformed the Canadian Market which returned 4.8% over the past year.


Shareholder returns

STILIndustryMarket
7 Day-9.2%-2.1%-0.3%
30 Day14.1%-15.0%-3.3%
90 Day-51.6%-32.4%-1.6%
1 Year-29.4%-29.4%-46.2%-46.2%8.5%4.8%
3 Year790.0%790.0%88.1%86.7%14.8%4.5%
5 Year1012.5%1012.5%306.6%306.6%26.6%8.1%

Price Volatility Vs. Market

How volatile is StillCanna's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is StillCanna undervalued compared to its fair value and its price relative to the market?

7.75x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate STIL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate STIL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: STIL is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: STIL is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate STIL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: STIL is overvalued based on its PB Ratio (7.7x) compared to the CA Pharmaceuticals industry average (1.8x).


Next Steps

Future Growth

How is StillCanna forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

87.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as StillCanna has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has StillCanna performed over the past 5 years?

-84.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: STIL is unprofitable, and losses have increased over the past 5 years at a rate of -84.9% per year.

Accelerating Growth: Unable to compare STIL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: STIL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.6%).


Return on Equity

High ROE: STIL has a negative Return on Equity (-394.88%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: STIL is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: STIL is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is StillCanna's financial position?


Financial Position Analysis

Short Term Liabilities: STIL's short term assets (CA$679.0K) exceeds its short term liabilities (CA$297.5K)

Long Term Liabilities: STIL's short term assets (679.0K) exceeds its long term liabilities (66.8K)


Debt to Equity History and Analysis

Debt Level: STIL's debt to equity ratio (2%) is considered satisfactory

Reducing Debt: Insufficient data to determine if STIL's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: STIL has a low level of unsold assets or inventory.

Debt Coverage by Assets: STIL's debt is covered by short term assets (assets are 10.2x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: STIL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: STIL has less than a year of cash runway if free cash flow continues to reduce at historical rates of -138.9% each year


Next Steps

Dividend

What is StillCanna's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage2.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate STIL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate STIL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if STIL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STIL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of STIL's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of StillCanna's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average management tenure


CEO

Jason Dussault 0

1.5yrs

Tenure

CA$14,000

Compensation

Mr. Jason Dussault has been the Chief Executive Officer of StillCanna Inc. since April 20, 2018 and Director since May 22, 2018 and serves as its President. Mr. Dussault was the Founder and served as the C ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Jason's total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensation vs Earnings: Insufficient data to compare Jason's compensation with company performance.


Management Age and Tenure

1.5yrs

Average Tenure

47yo

Average Age

Experienced Management: STIL's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Age and Tenure

0.8yrs

Average Tenure

Experienced Board: STIL's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: STIL insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCA$11,58201 Oct 19
Jason Dussault
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares30,000
Max PriceCA$0.39
BuyCA$50,79628 Aug 19
Jason Dussault
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares80,000
Max PriceCA$0.76

Ownership Breakdown


Management Team

  • Richard Haslinger (55yo)

    Consultant

    • Tenure: 4.1yrs
  • Adam Kim (46yo)

    Promoter

    • Tenure: 0yrs
  • Jason Leikam (48yo)

    Consultant

    • Tenure: 4.1yrs
  • Jason Dussault

    CEO, President & Director

    • Tenure: 1.5yrs
    • Compensation: CA$14.00k
  • Joel Leonard (33yo)

    Chief Financial Officer

    • Tenure: 1.4yrs
    • Compensation: CA$15.00k
  • Shae De Jaray

    COO, Senior Engineer & Director

    • Tenure: 0.3yrs
  • Marc Crimeni

    • Tenure: 0yrs

Board Members

  • Warren Robinson

    Independent Director

    • Tenure: 0.4yrs
  • Bill MacDonald (51yo)

    Independent Director

    • Tenure: 0.3yrs
  • Jason Dussault

    CEO, President & Director

    • Tenure: 1.5yrs
    • Compensation: CA$14.00k
  • C.K. Cheung

    Member of Advisory Board

    • Tenure: 3.3yrs
  • Shae De Jaray

    COO, Senior Engineer & Director

    • Tenure: 0.3yrs
  • Krystyna Skalicka-Wozniak

    Member of Advisory Board

    • Tenure: 0.8yrs
  • Krzysztof Wojtanowski

    Member of Advisory Board

    • Tenure: 0.8yrs
  • Lidia Grabowska

    Member of Advisory Board

    • Tenure: 0.8yrs
  • Thomas Svensson

    Member of Advisory Board

    • Tenure: 0.8yrs
  • Bogdan Wenta

    Member of Advisory Board

    • Tenure: 0.8yrs

Company Information

StillCanna Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: StillCanna Inc.
  • Ticker: STIL
  • Exchange: CNSX
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$49.339m
  • Shares outstanding: 110.87m
  • Website: https://www.stillcanna.com

Location

  • StillCanna Inc.
  • 905 West Pender Street
  • Suite 503
  • Vancouver
  • British Columbia
  • V6C 1L6
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
STILCNSX (Canadian National Stock Exchange)YesCommon SharesCACADMay 2012
484DB (Deutsche Boerse AG)YesCommon SharesDEEURMay 2012
SCNN.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMay 2012

Biography

StillCanna Inc., a life sciences company, focuses on cannabidiol extraction in Europe. The company was formerly known as EVI Global Group Developments Corp. and changed its name to StillCanna Inc. in March ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/24 00:46
End of Day Share Price2019/10/23 00:00
Earnings2019/04/30
Annual Earnings2018/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.